PreOncology's Bid to Find Cancer Before Stage I: A New Frontier?

WEST PALM BEACH, Fla. – July 01, 2026 – For decades, the fight against cancer has largely been a reactive one, an urgent response triggered by a lump, an abnormal scan, or the onset of symptoms. By then, the disease may have already progressed. A new Florida-based company, PreOncology, is aiming to fundamentally rewrite this script by launching what it calls a new medical subspecialty focused on finding cancer before it even reaches Stage I.

"If a cardiologist waited until a patient suffered a massive heart attack before becoming involved, we would consider that a failure of the healthcare system," said Dr. Jose Barreau, a board-certified medical oncologist and Co-Founder of PreOncology. "Yet in oncology, we typically don't meet patients until after cancer has already formed."

This powerful analogy cuts to the core of the company's mission: to shift cancer care from late-stage treatment to proactive, continuous surveillance. By applying the expertise of oncologists before a diagnosis, the company hopes to identify the disease at its earliest, most curable point, challenging a screening system that still relies heavily on population averages like age.

A New Paradigm in Cancer Care

PreOncology's model moves beyond the one-size-fits-all approach that leaves many cancers without a routine screening pathway. The company has introduced the PreOncology Program™, an oncologist-led service designed to provide continuous, individualized cancer prevention and detection. This isn't about simply ordering more tests; it's about a fundamental re-evaluation of personal risk.

At the heart of this new paradigm is the concept of "Oncologic Biological Drift." The company uses this term to describe the way an individual's cancer risk profile changes over time due to a combination of genetics, lifestyle, and environmental exposures. PreOncology aims to monitor this drift continuously, looking for the earliest signals that may indicate a pre-cancerous state or a nascent tumor.

"Cancer prevention is not about ordering more tests," explained Dr. Amit Gupta, Co-Founder and Chief Scientific Officer of PreOncology. "It is about knowing which tests make sense, for which patients, when to use them, and what to do with the information. A blood test, scan, or genetic result is a tool—not an answer. The value comes from the clinical program built around it."

The Stage Alpha Operating System: AI Meets Oncology

The technological engine driving this ambitious program is the patent-pending Stage Alpha Operating System™, a clinical intelligence platform that integrates vast amounts of data to create a dynamic picture of a patient's health. The system is built on three core capabilities:

1. Dynamic Risk Engine: This AI-powered engine creates a highly personalized cancer risk assessment. It synthesizes data from whole genome sequencing, a patient's clinical and family history, lifestyle factors, and biomarkers. To build its models, the company utilized a massive dataset of approximately 3.1 million de-identified patient records from major research studies. For lung cancer alone, the model incorporates data from over 611,000 individuals, providing a deep evidence base for its predictions.

2. Protocol Optimization: Based on the risk assessment, the system uses what it calls "detection mathematics" to generate a personalized surveillance strategy. This determines which screening technologies—be it advanced imaging, liquid biopsies, or other biomarkers—are most appropriate for an individual, when they should be performed, and how often. This stands in stark contrast to static, age-based screening guidelines.

3. Signal Review: Crucially, the program is not fully automated. A dedicated "Signal Board" of board-certified medical oncologists reviews abnormal findings and emerging biological signals. This human-in-the-loop oversight is designed to interpret complex results, prevent unnecessary alarm, and help the patient's primary physician determine the most appropriate next steps, from watchful waiting to a diagnostic workup.

"Cancer risk is dynamic, not static," noted Dr. Russell Rockne, Director of Mathematical Oncology at City of Hope and a scientific advisor to PreOncology. "As we better understand tumor biology, individual risk, and the performance of detection technologies, there is an opportunity to move beyond one-size-fits-all screening toward surveillance strategies that are mathematically tailored for each person."

The Competitive Landscape of Early Detection

PreOncology enters a fiercely competitive and rapidly innovating market. The field of multi-cancer early detection (MCED) is dominated by heavily funded players like Grail, whose Galleri blood test can screen for over 50 types of cancer, and Guardant Health with its Shield test. These companies primarily focus on developing a single, powerful liquid biopsy test.

PreOncology seeks to differentiate itself by being a comprehensive clinical program rather than a single product. Its leaders stress that the company is "technology agnostic," meaning it can incorporate the best available screening tools—including tests from competitors—into its personalized surveillance protocols. The unique selling proposition is the integrated system: the AI-driven risk assessment, the customized surveillance plan, and the expert oncologist oversight. This positions the company less as a test developer and more as a specialized clinical service provider that leverages the entire arsenal of modern diagnostics.

Promise and Practical Hurdles: Validation, Access, and Cost

While the promise of catching cancer at "Stage Alpha" is immense, PreOncology faces significant practical hurdles. The most pressing challenge is clinical validation. While the concepts of using AI and genomics are well-supported in academic literature, and the company touts its internal validation on large datasets, independent, peer-reviewed studies demonstrating that the complete Stage Alpha Operating System leads to better outcomes—fewer late-stage cancers and lower mortality—will be critical for broad adoption by the medical community.

Furthermore, the initial delivery model raises serious questions about equitable access. The program is launching through concierge and direct primary care (DPC) practices, which typically serve patients who pay out-of-pocket membership fees for premium care. This immediately limits access to those with the financial means, potentially creating a two-tiered system of cancer prevention. Health policy experts caution that such models, while effective for early adoption of innovation, can exacerbate existing healthcare disparities.

PreOncology acknowledges a long road ahead, stating its intention to pursue regulatory pathways for its software as a clinical decision support tool and to partner with health systems, employers, and payers to make the program more broadly available. Securing insurance coverage will be a monumental task, requiring robust data on clinical utility and cost-effectiveness.

The company's ambition to redefine the timeline of cancer care represents a powerful and logical evolution in medicine. By combining artificial intelligence, genomics, and expert clinical oversight, it is building a framework for a future where cancer is managed proactively, not reactively. The ultimate success of this vision, however, will depend not only on the power of its technology but on its ability to prove its value and make it accessible to all who could benefit.